Vascular Effects of GI262570X (PPAR-γ agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month,13-week,27-week and 2-year Oral Toxicity Studies
Free accessReview articleFirst published online June, 2002
Vascular Effects of GI262570X (PPAR-γ agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month,13-week,27-week and 2-year Oral Toxicity Studies
We describe and discuss microscopic findings in the brown adipose tissue (BAT) blood vessels of Han Wistar rats treated with GI262570X, a peroxisome proliferator-activated receptor- γ agonist (PPAR-γ agonist) by oral gavage for 28 days, 13 weeks, 27 weeks, and 2 years. Review of these studies revealed a consistent vascular change, consisting of multifocal fatty infiltration in the BAT of treated rats. A similar vascular change was not seen in other vessels or organs. Microscopically, fatty infiltration was characterized primarily by round, clear vacuoles within the tunica media and/or tunica adventitia of small and medium-sized arteries and arterioles. Occasionally, these vacuoles had peripherally located nuclei and morphologically resembled adipocytes, suggesting a well-characterized PPAR effect (ie, differentiation of stem cells or preadipocytes into mature adipocytes). However, administration of GI262570X up to 2 years failed to induce more severe or progressive lesions in the blood vessels of rat BAT and, in particular, did not result in induction of any atherosclerotic-like lesions or foam cell infiltration. At the longer exposure, there was an apparent reduction of severity and/or incidence, indicating a possible adaptive response. These results suggest that the possibility of generating atherosclerotic-like lesions through prolonged treatment of GI262570X (PPAR-γ agonist) is highly unlikely in rats.
Afzelius BA (1970). Brown adipose tissue: Its gross anatomy, histology, and cytology. In: Brown Adipose Tissue, Lindberg O (ed). Elsevier, New York, pp 1—32.
2.
Benson S., Wu J., Padmanabhan S., Kurtz TW, Pershadsingh HA (2000). Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator Troglitazone. Am J Hypertens13: 74—82.
3.
Boring L., Gosling J., Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF (1997). Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest100: 2552—2561.
4.
Braissant O. , Foufelle F., Scotto C., Dauca M., Wahli W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology137: 354—366.
5.
Brooks JJ, Perosio PM (1992). Adipose tissue. In: Histology for Pathologists, Sternberg SS (ed). Raven Press, New York, pp 33—60.
6.
Chawla A., Boisvert WA, Lee CH, Laffitte BA, Barak Y., Joseph SB, Liao D., Nagy L., Edwards PA, Curtiss LK, Evans RM, Tontonoz P. (2001). A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell7: 161—171.
7.
Chen Z., Ishibashi S., Perrey S., Osuga JI, Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., Yamada N. (2001). Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol21: 372—377.
8.
Collins AR, Meehan WP, Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh WA, Law RE (2001). Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol21: 365—371.
9.
Cominacini L. , Garbin U., Fratta Pasini A., Davoli A., Campagnola M., Rigoni A., Tosetti L., Cascio V. (1999). The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity. Cell Adhes Commun7: 223—231.
10.
Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart JC, Najib J., Duriez P., Staels B. (1999). Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res85: 394—402.
11.
Elangbam CS, Tyler RD, Lightfoot RM (2001). Peroxisome proliferator-activated receptors in atherosclerosis and inflammation—An update. Toxicol Pathol29: 224—231.
12.
Goetze S., Xi XP, Kawano H., Gotlibowski T., Fleck E., Hsueh WA, Law RE (1999). PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J CardiovasPharmacol33: 798—806.
13.
Goetze S., Xi XP, Graf K., Fleck E., Hsueh WA, Law RE (1999). Troglitazone inhibits angitensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett452: 277—282.
14.
GrafK., Xi XP, Hsueh WA, Law RE (1997). Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett400: 119—121.
15.
Gu L., Okada Y., Clinton SK, Gerard C., Sukhova GK, Libby P., Rollins BJ (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice . Mol Cell2: 275— 281.
16.
Hattori Y., Hattori S., Kasai K. (1999). Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension33: 943—948.
17.
Hupfeld CJ, Weiss RH (2001). TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab281: E207—216.
18.
Jiang C., Ting AT, Seed B. ( 1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature391: 82—86.
19.
Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., Watanabe T. (1999). Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial cells: A possible role for PPAR gamma in endothelial function. Biochem Biophys Res Commun258: 431—435.
20.
Koshiyama H. , Shimono D., Kuwamura N., Minamikawa J., Nakamura Y. (2001). Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab86: 3452—3456.
21.
Law RE, Meehan WP, Xi XP, Graf K., Wuthrich DA, Coats W., Faxon D., Hsueh WA (1996). Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest98: 1897—1905.
22.
Law RE, Goetze S., Xi XP, Jackson S., Kawano Y., Demer L., Fishbein MC, Meehan WP, Hsueh WA (2000). Expression and function of PPAR-γ in rat and human vascular smooth muscle cells. Circulation101: 1311—1325.
23.
Loviscach M. , Henry RR (1999). Clinical significance of proliferator-activated receptors in health and disease. Medscape DiabEndocrinol1—14.
24.
Marx N., Mach F., Sauty A., Leung JH, Sarafi MN, Ransohoff RM, Libby P., Plutzky J., Luster AD (2000). Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T-cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol164: 6503—6508.
25.
Marx N., Schonbeck U., Lazar MA, Libby P., Plutzky J. (1998). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res83: 1097— 1103.
26.
Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. (1998). Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol153: 17—23.
27.
Michalik L. , Wahli W. (1999). Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions . Curr Opin Biotechnol10: 564— 570.
28.
Minamikawa J., Tanaka S., Yamauchi M., Inou D., Koshiyama H. (1998). Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type-2 diabetes. J Clin Endocrinol Metab83: 1818—1820.
29.
Moore KJ, Rosen ED, Fitzgerald ML, Randow F., Andersson LP, Altshuler D., Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW (2001). The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nature Med7: 41—47.
30.
Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., Ishida T., Takahara J. (1999). Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells . FEBS Lett454: 27—30.
31.
Nagy L., Tontonoz P., Alvarez JGA, Chen H., Evans RM (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell93: 229—240.
32.
Ohta MY, Nagai Y., Takamura T., Nohara E., Kobayashi K. (2000). Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells. Metab Clin Exper49: 163—166.
33.
Pasceri V., Wu HD, Willerson JT, Yeh ETH (2000). Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation101: 235—238.
34.
Plutzky J. (1999). Atherosclerotic plaque rupture: Emerging insights and opportunities. Am J Cardiol84: 15J—20J.
35.
Rajavashisth T., Qiao JH, Tripathi S., Tripathi J., Mishra N., Hua M., Wang XP, Loussararian A., Clinton S., Libby P., Lusis A. (1998). Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest101: 2702—2710.
36.
Ricote M., Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature391: 79—82.
37.
Tontonoz P. , Nagy L., Avarez JGA, Thomazy VA, Evans RM (1998). PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell93: 241—252.
38.
Zaretskaia MV, Zaretsky DV, Shekhar A., DiMicco JA (2002). Chemical stimulation of the dorsomedial hypothalamus evokes non-shivering thermogenesis in anesthetized rats. Brain Res928: 113—125.
